MBOT חוב כולל להון Microbot Medical

Microbot Medical Inc. (MBOT) creates innovative solutions for microrobotic surgeries using its proprietary LIBERTY platform for safe endovascular interventions. High barriers to entry are driven by the complexity of FDA certification and the specifics of surgeon training. This historical price chart demonstrates a total debt-to-equity ratio, which currently stands at 0.01. Business stability is ensured by an independent product cycle, making the company a resilient defensive asset.

The ratio is calculated as the sum of all liabilities divided by the company's equity. This metric determines the business's dependence on external borrowings and the level of financial risk. For Microbot Medical Inc. (MBOT), which develops robotic systems, monitoring this parameter is critical until the product commercialization stage. An increase in the total debt-to-equity ratio may signal a liquidity shortage, while a downward trend confirms the strengthening of the company's financial autonomy.